

## Lectio Magistralis

---

# prof. Peter Goodfellow

## “Sex Determination”

---

dedicated to  
**Giovanna Camerino**

Scholar of the genetics of sex determination

Pavia, Wednesday 11 March 2026, 11:00 a.m.  
Arturo Falaschi Lecture Hall, IGM – CNR Pavia  
Via A. Ferrata, 1



**Peter Goodfellow** BSc; DPhil, DSci. Professor of Genetics, Cambridge University; Senior Vice President Research, GSK; Venture Partner, Abingworth Life Sciences. Member of FRS, FAcadMedSci, EMBO Fellow. Principal Research Fellow, ICRF; Balfour.

Professor Peter Goodfellow has worked in both Academia and Industry. He spent 13 years at Imperial Cancer Research Institute in London (now part of CRUK) and 4 years as Balfour Professor of Genetics at Cambridge University. Subsequently, Peter worked for a decade in the pharmaceutical industry, serving first as worldwide head of Research for SmithKline Beecham and then Senior Vice-President of Discovery Research at GlaxoSmithKline. He is also a Founder of several biotechnology companies, most recently GammaDelta Therapeutics, Adaptate Biologics (both acquired by Takeda) and Cytospire Therapeutics. Currently, Peter is a Venture Partner at Abingworth Life Sciences.

Amongst other honours, Peter has been elected as a Fellow of The Royal Society, EMBO and the Academy of Medical Sciences. He has been awarded the Louis Jeantet Prize for Medicine (with Dr R Lovell-Badge), the Francis Amory Prize of the American Academy of Arts and Sciences (with Dr R.Lovell-Badge) and a Doctorate in Science (Honoris Causa) from Bristol University. Peter has been a visiting professor at Birkbeck College, University College London, Bristol University and University of Kent. Previously, Peter was the Mok Hing-Liu Visiting Professor Hong Kong University and Scholar in Residence at Rockefeller University.